Investor Alert - Medical Marijuana Inc. MJNA Cannot Sell

New Post Public Reply Private Reply Replies (0) Message Board
cb11
Investor Alert - Medical Marijuana Inc. MJNA Cannot Sell !!



Cannabis · Hemp · Hanf · Cannabinoids · THC · CBD · Medical · Medicinal ·

FDA · NHI · EMA · JMA · Patient · Patent · License · Audit · Report · SEC ·



MMJ = Medical Marijuana or CBD Hemp !



Medical Marijuana Inc. - Cannot Sell MMJ or CBD Products !!



Seems majority of its Investors mentally very

dependent, that normal commonsense market

considerations are not possible. Just Pumpers

fake oriented !

For example most of them like to believe, that

Registered MMJ or CBD Patients for Pain-Therapy

will pay annually about $ 8000.- to MJNA, when

they at any Pharmacy as even FDA Approved can

get for $ ZERO the principally much more expensive

CBD Sativex which is also killing Pain & Cancer as

it already worldwide does, but FDA Approved the

US Health Insurances completely paying for it !!



100% sure, 99% of Registered Patients are not

willing to pay annually $ 8000.- to MJNA as they

don’t need or not even have the money or with

that money better go for Holiday or do with it

something else in life important, instead of

paying for Companies such as MJNA !



Famous CBD Sativex is now at every Pharmacy available !!!



MJNA at present has the most exposure and

because of this it gets most affected, but for

fairness its necessary to mention that any MJ

Company with desire to sell MMJ Products get

affected by its None FDA Approved Products

the US Health Insurances Therefore Not Pay !!

MJNA is additionally under SEC Investigations.



Small US MJ Companies not able to change

the Handling of the US Health Insurances !!



This for All Investors to think very well about !



PS : GW Pharmaceuticals the producer of its

patented Sativex, by its owner consortium is

related to Big Global Player Companies with

worldwide annual Revenue of about $ 168 Bn.

This only for knowing with what the small US

MJ Companies really dealing with and to see

the present situation as the beginning only !

For the additional Wellness- Products, there

will be coming Companies as Nestle, Unilever,

RedBull, Etc. also to keep well in mind !!

Its not that simple or easy as Pumpers Think !

Additionally New Fed. US MJ Laws to expect,

will KILL MJ THC Content Wellness Products !



MJNA’s “Cibaderm” is a Big Global Player NOVARTIS Brand ; Happy Lawsuits !!



Additionally as known the SEC knocking at MJNA Doors !!

They Call That Inquiry When Doing Investigations ¨!!!



This With Compliments By On2_addict Presented.





As Investor if you may get or got harmed by any Short- Talk Blackmailing

or Misleading MB Members, just add www. to the Posts- Link to send and

File your Claims at ic3.gov CIA & FBI Branch - Internet Crimes, they help !



If by Company Abused, Mislead, Etc., Contact SEC Hotline - Washington !



Special Company History !!

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 19

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading
Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 14

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 11

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 10

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 20

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 17

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 8

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading

Top 5 Most Recently Viewed Articles

Sera Prognostics to Showcase Innovations at RBC Healthcare Event

Updated Category News Views 112

Sera Prognostics to Showcase Innovations at RBC Healthcare Event Sera Prognostics Inc., known as The Pregnancy Company (NASDAQ: SERA), is focused on enhancing maternal and neonatal health through innovative pregnancy biomarker information. The company has recently announced its participation at an important healthcare event, highlighting its ongoing commitment to improve...

Continue Reading
Unlocking AI Potential: Insights from Netcracker CEO Andrew Feinberg

Updated Category News Views 268

Exciting Keynote at GITEX Global 2024 Netcracker Technology is buzzing with excitement as Andrew Feinberg, the Chairman and CEO, prepares for a pivotal keynote presentation at one of the largest tech events in the world, GITEX Global 2024. This annual technology conference draws innovators, industry leaders, and enthusiasts keen on understanding the future of technology....

Continue Reading
Adherium Empowers COPD and Asthma Management with iCARE Study

Updated Category News Views 147

Adherium's Transformative iCARE Study Results The innovative strides made by Adherium Limited (ASX:ADR) in respiratory health have shown promising outcomes as seen in the iCARE study. This study investigated the effectiveness of their Hailie® Smartinhaler® technology in improving adherence among patients suffering from chronic obstructive pulmonary disease (COPD) and...

Continue Reading
Medius Highlights Impending Finance Challenges Post AI Launch

Updated Category News Views 243

AI Fraud Concerns Elevate in the Finance Sector Medius has unveiled alarming findings indicating that nearly one in three finance professionals are unable to spot AI-generated fake receipts. This revelation surfaces amidst rising fears of fraud escalation following the recent launch of GPT-5.0. With the capabilities of AI continuously improving, finance teams must prepare...

Continue Reading
TD Cowen Sustainably Endorses Abbott Labs with Robust Price Target

Updated Category News Views 59

TD Cowen Affirms Buy Rating on Abbott Laboratories TD Cowen has reaffirmed its Buy rating on Abbott Laboratories (NYSE: ABT), maintaining a price target of $130.00 for the healthcare company's shares. This positive stance hinges on expectations that Abbott's upcoming third-quarter results will either meet or surpass current market predictions, allowing the company to...

Continue Reading